Figure 4. Pathways and novel functional groups mutated in advanced thyroid tumors.
Expanded oncoprints of genes belonging to the indicated functional categories, as defined in Figure 1G. Samples are divided by tumor type (ATC or PDTC) within each panel. Only altered cases, out of 117 tumors, are shown. Missense, truncating, and in-frame mutations are represented as green, black, and brown squares, respectively. (A) PI3K/AKT/mTOR pathway (includes PIK3CA, PTEN, PIK3C2G, PIK3CG, PIK3C3, PIK3R1, PIK3R2, AKT3, TSC1, TSC2, and MTOR); (B) SWI/SNF chromatin remodeling complex (ARID1A, ARID1B, ARID2, ARID5B, SMARCB1, PBRM1, and ATRX); (C) HMTs (KMT2A, KMT2C, KMT2D, and SETD2); and (D) MMR (MSH2, MSH6, and MLH1). (E) Percentage of tumors altered for each functional category and tumor type.